BIN1 Gene Expression Prognostic Marker for Heart Failure Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack effective means to assess the risk of poor outcomes in congestive heart failure patients, particularly for those awaiting heart transplants or undergoing mechanical assist device support, as they fail to accurately evaluate cardiac health and treatment efficacy.
Innovation Solution
The method involves assaying BIN1 expression levels in heart tissue samples to determine the risk of poor outcomes, using BIN1 expression levels relative to internal control genes like CaV1.2 to calculate an Intrinsic Disease Factor (IDF), which correlates with cardiac mortality and treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to assess congestive heart failure patients, then the diagnostic process is simple and widely available, but the accuracy in predicting poor outcomes and evaluating treatment efficacy is insufficient
Solution Approach 1:
The patent changes the parameter being measured from general clinical indicators to specific gene expression levels (BIN1 and CaV1.2). By quantifying these molecular parameters in heart tissue samples, the diagnostic method achieves higher precision in predicting poor outcomes and evaluating treatment response in congestive heart failure patients.
2Reliability
If BIN1 expression level assaying is implemented to determine patient risk, then the prognostic accuracy is improved, but the diagnostic complexity and resource requirements increase
Solution Approach 1:
The patent uses gene expression levels as intermediary biomarkers that mediate between the complex biological state of heart failure and the measurable diagnostic output. By measuring BIN1 and CaV1.2 expression as intermediate indicators, the method translates complex pathological processes into quantifiable prognostic data without requiring direct observation of all underlying mechanisms.
3Measurement precision
If multiple gene expression levels are measured and normalized to calculate IDF, then the prognostic precision is enhanced, but the time and computational resources required increase
Solution Approach 1:
The patent performs preliminary normalization of gene expression data using the CaV1.2 gene as a reference before calculating the final IDF metric. This preliminary standardization step establishes a baseline that simplifies subsequent risk assessment and allows for faster interpretation of prognostic results without requiring extensive post-processing analysis.
Data Source
AI summary
The present disclosure provides methods involving use of BIN1 expression levels, in heart tissue, in evaluating the risk of a poor outcome in a patient diagnosed with congestive heart failure. The methods finds use in evaluating patients who are heart transplant candidates as well as in assessing therapy options and efficacy of treatment in congestive heart failure patients.